December 20, 2017 / TheNewswire / LeenLife Pharma International - The Company is pleased to announce the purchase of production equipment for the manufacture of its omega 3 products. A purchase order has been issued and accepted by BioCube Corporation Ltd. (“BioCube”), an Australian company with offices in British Columbia, to purchase equipment to manufacture the Company’s Omega 3 products based on flax seed oil, which have been used in various food products.

BioCube, offers LeenLife Pharma a on or off-grid platform that provides seamless integration into the commercial production process of LeenLife Pharma’s proprietary and industry leading Omega-3 formulations in the form of oil, emulsion and powders at a capacity of 2.4 million liters per year.

The Company had entered into an exclusive agreement with BioCube (see news release dated October 17, 2017) having developed a proprietary processing plant, having intellectual property including patents, patent applications and proprietary information and technical information (the “BioCube Processor”). The BioCube Processor has been modified to process LeenLife’s proprietary technology

The Company is totally satisfied that the efficiency of the BioCube and the BioCube process will address concerns of food grade quality control, cost, production quotas and handling. The Company is immediately setting up operations in the Vancouver area. It is anticipated that the first BioCube unit will be commissioned in January 2018. Additional BioCubes will be purchased as increases in demand are calculated. Plans are also in the works to purchase BioCube units for operations in the United States. The Company has decided for the operation of a subsidiary in the United States, along with suitable management. The Canadian operation will start production followed up with operations in the United States.

About the Company and the Market:

LeenLife products are extracted from flax seeds, a plentiful grain, an organic and a non-animal source. The products can be used as a food additive or as a nutraceutical and have been used in making bread, noodles, cheese, yogurt, juice and milk products for the European market. Their industry leading Omega 3 product formulations are of the highest quality with no cholesterol and toxic substances and are offered as an oil, emulsion and powder.

The global Omega 3 market was valued at 10 billion USD in 2016 and is expected to reach 16 billion USD by the end of 2023, growing at a CAGR of 7.57% between 2016 and 2023.

For more information, please contact:

Stan Lis, CEO

Tel:  604 764-0518

E-mail: slis@leenlifepharma.com

Forward-looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including statements that address the Transaction and the meeting of shareholders and those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals.